Hard Tech Investment Continues to Heat Up: H1 2026 Data Interpretation

On July 26, 2026, PitchBook, a globally renowned investment data platform, released its latest report: In the first half of 2026, global venture capital investment in hard tech sectors (including semiconductors, quantum computing, biotech, new energy, new materials, etc.) reached $68 billion, up 35% year-on-year, hitting an all-time high for the period. Among them, quantum computing and synthetic biology led with $12 billion and $9.5 billion in funding, respectively, becoming the two most sought-after tracks by capital.

This data marks the shift of hard tech investment from the "concept hype" stage to the "substantive implementation" stage. Top institutions such as Sequoia Capital, SoftBank Vision Fund, and Tiger Global Management have set up dedicated hard tech funds, with single investments often reaching hundreds of millions of dollars. For example, in June 2026, U.S. quantum computing startup Atom Computing completed an $800 million Series D financing, achieving a post-investment valuation of $8.5 billion; domestic synthetic biology company BGI's subsidiary MGI received a $1.5 billion strategic investment to expand its gene editing and biomanufacturing platforms.

Core Logic Behind Heavy Allocation in Hard Tech: Technology Inflection Points and Policy Resonance

Why has hard tech become a unanimous direction for global capital? The underlying logic can be understood from three dimensions.

1. Accelerating Technological Breakthroughs

Hard tech investment is not an overnight affair but is based on judgments of key technology "inflection points." Take quantum computing as an example: In 2025, Google announced its Sycamore processor achieved 1,000 qubits, surpassing the computational limits of classical supercomputers; in July 2026, IBM launched its new-generation quantum processor Heron, further reducing error rates. These breakthroughs make it possible for quantum computing to move from labs to commercial applications, driving investment throughout the upstream and downstream industrial chains. Similarly, in synthetic biology, CRISPR gene-editing technology has entered Phase II clinical trials, and AI-assisted protein design has significantly reduced R&D costs, prompting capital influx.

2. National Strategy and Policy Dividends

Governments worldwide view hard tech as core to future competitiveness. China's 14th Five-Year Plan explicitly lists quantum information, biotechnology, and new materials as frontier priorities; the U.S. CHIPS and Science Act of 2026 allocates an additional $50 billion for semiconductor and AI basic research; the EU's Horizon Europe program has increased its budget share for hard tech related investments to 40% for 2025-2027. Policy support not only provides funding but also reduces corporate risks through tax incentives, talent introduction, and industrial park construction, encouraging long-term institutional allocation.

3. Macroeconomic Environment Driving Asset Allocation Shift

With low global interest rates in 2026 and declining yields on traditional assets, institutional investors are urgently seeking high-return targets. Hard tech, with its dual attributes of "long-term high growth + technical barriers," is seen as a quality asset to weather economic cycles. According to Preqin research, the allocation to hard tech by global pension funds and sovereign wealth funds rose from 5% in 2023 to 12% in H1 2026. Notably, the Canada Pension Plan Investment Board (CPPIB) announced it would increase its hard tech investment share to 20% over the next three years.

Track Breakdown: Why Quantum Computing and Synthetic Biology Are the Hottest?

Among all hard tech sub-sectors, why do quantum computing and synthetic biology stand out?

Quantum Computing: From "Concept" to "Application"

The investment logic of quantum computing lies in its disruptive potential. While traditional computers follow Moore's Law, quantum computers leverage superposition and entanglement to achieve exponential acceleration in drug discovery, materials design, cryptography, and more. In H1 2026, more than half of quantum computing financing events focused on quantum software and algorithms, signaling the industry's shift from hardware manufacturing to commercial applications. For example, Canadian quantum software company 1QBit partnered with Pfizer, using quantum algorithms to shorten the molecular simulation time for new drugs from six months to three days, validating its commercial value.

However, quantum computing also faces risks such as high R&D investment, technical route uncertainty, and talent scarcity. Current mainstream technical paths include superconducting, trapped ion, and photonic qubits, with no absolute competitive advantage yet established. Investors need long-term patience, and the first commercial-grade quantum computer is expected to emerge around 2030.

Synthetic Biology: Reshaping Industrial Value Chains

Synthetic biology modifies microbial cell factories to produce everything from biodegradable plastics and lab-grown meat to natural flavors and anticancer drugs. In 2026, the industry achieved dual breakthroughs in cost reduction and large-scale production. Domestic synthetic biology leader MGI launched a new-generation gene synthesizer, reducing cost to $0.01 per base—one-tenth of the 2019 level. Additionally, the EU passed the Synthetic Biology Promotion Act, mandating that 30% of plastics be replaced by bio-based materials by 2030, directly opening a trillion-dollar market.

Investment opportunities extend beyond biomanufacturing companies to upstream suppliers of gene-editing tools (CRISPR), cell factory design platforms, and directed enzyme evolution technologies. Key risks include regulatory uncertainty (e.g., gene synthesis safety regulations) and slower-than-expected commercialization progress.

Investor Strategies: How to Heavily Allocate to Hard Tech?

For institutional and individual investors, heavy allocation to hard tech is not simply buying stocks or funds but requires a systematic approach.

  • Hold Long-Term, Avoid Short-Term Volatility: Hard tech companies typically need 7-10 years to become profitable. Investors should ignore short-term stock price fluctuations and focus on technology R&D milestones and commercialization progress.
  • Diversify Tracks, Reduce Single Risk: Sub-tracks such as semiconductors, new energy, biotech, quantum computing, and AI have low correlation. A suggested allocation: 40% mature tracks (semiconductor equipment, photovoltaics), 30% growth tracks (AI chips, innovative drugs), and 30% frontier tracks (quantum computing, brain-computer interfaces).
  • Combine Blue Chips and Startups: Invest in mature leaders (e.g., NVIDIA, TSMC, MGI) as stabilizers, while also allocating through venture capital funds or dedicated ETFs to early-stage startups (e.g., Quantum Machines, Zipline Medical) to balance risk and return.
  • Leverage Policy Tools: Domestically, instruments like the Science and Technology Innovation Fund and STAR Market ETFs; overseas, funds like ARKK (focusing on disruptive innovation) can lower research barriers.

Future Outlook: Long-Term Trends in Hard Tech Investment

Looking ahead to H2 2026 and beyond, hard tech investment will show three major trends:

First, deep convergence: Hard tech fields are increasingly intersecting, such as AI + biopharma (AlphaFold), quantum + materials design, and new energy + smart manufacturing. Single technologies can hardly develop independently; investors should focus on ecosystem-oriented companies.

Second, intensifying global competition: The "technology arms race" among China, the U.S., and Europe in hard tech is white-hot. Investors must consider geopolitical risks, such as chip export controls and bio-data security laws, and are advised to favor market-neutral or domestic advantage industries.

Third, diverse exit channels: SPACs, IPOs, and M&A exit mechanisms are increasingly mature. In H1 2026, 12 hard tech companies went public via SPACs, six of which currently have market caps higher than at listing. Investors can look for arbitrage opportunities in Pre-IPO rounds.

In summary, heavy allocation to hard tech is not just chasing trends but a deep understanding of technological trajectories and a belief in long-term value. As Sequoia Capital partner Roelof Botha said: "Hard tech investment is like planting a tree—the first ten years grow invisibly underground, but once it breaks through, it's unstoppable." For visionary investors, now is the best time to sow seeds.